eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
1/2020
vol. 6
 
Share:
Share:
abstract:
Review article

Pregabalin and duloxetine in the treatment of neuropathic pain – why the use of off-label drugs is consistent with the standards of management and current medical knowledge

Jarosław Woroń
1, 2

1.
Kliniczny Oddział Anestezjologii i Intensywnej Terapii nr 1, Centrum Urazowe Medycyny Ratunkowej i Katastrof, Szpital Uniwersytecki w Krakowie
2.
Zakład Farmakologii Klinicznej Katedry Farmakologii, Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum, Kraków
Online publish date: 2020/04/21
View full text Get citation
 
Neuropathic pain is a symptomatic diagnosis. The cause of neuropathic pain may be known and is usually an infection or injury. However, its cause is very often unknown in neuropathic pain. Neuropathic pain is characterised by altered reactivity of neurons at many levels of the nervous system – from peripheral nerve fibres to the cerebral cortex. The choice of individual drugs should result from both the clinical picture of the disease, the location and intensity of pain, comorbidities and other drugs used by the patient. A significant proportion of drugs used in the treatment of neuropathic pain is used off-label; hence, it is important to make the patient aware of the role of antiepileptic and antidepressant drugs in the treatment of neuropathic pain.
keywords:

neuropathic pain, pharmacotherapy, off-label use

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.